Pola-ZR2P in Previously Untreated DLBCL
NCT06664411
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG:
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
Sponsor
Navy General Hospital, Beijing